Literature DB >> 25099109

The importance of visual field testing in idiopathic intracranial hypertension.

Michael Wall.   

Abstract

Idiopathic intracranial hypertension (IIH) is a disease of unknown cause typically affecting obese women in the childbearing years. Although headache is the most common symptom, the major morbidity of IIH is visual loss, with 5% to 10% of patients progressing to blindness. While about 95% of patients with IIH have visual loss documented by perimetry, only about one-third notice their visual loss because most loss occurs in the peripheral visual field. Since treatment decisions in IIH are made primarily by changes in visual field function, serial perimetry is the most critical test to obtain when following patients with IIH. This article describes the role of visual field testing in the monitoring of IIH patients in clinical practice, including its importance in communication among providers.

Entities:  

Mesh:

Year:  2014        PMID: 25099109     DOI: 10.1212/01.CON.0000453302.20110.29

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  4 in total

1.  Clinical Reasoning: A 20-year-old man with headache and double vision.

Authors:  Khaled Moussawi; Anoopum Gupta; Haatem Reda
Journal:  Neurology       Date:  2016-10-11       Impact factor: 9.910

2.  Diffusion tensor imaging of the optic disc in idiopathic intracranial hypertension?

Authors:  Halil Onder
Journal:  Neuroradiology       Date:  2018-11-28       Impact factor: 2.804

Review 3.  Update on the Diagnosis and Treatment of Idiopathic Intracranial Hypertension.

Authors:  Sarah R Ahmad; Heather E Moss
Journal:  Semin Neurol       Date:  2019-12-17       Impact factor: 3.420

4.  Bridging the Gap between Ophthalmology and Emergency Medicine in Community-Based Emergency Departments (EDs): A Neuro-Ophthalmology Guide for ED Practitioners.

Authors:  Kristina Thomas; Cindy Ocran; Anna Monterastelli; Alfredo A Sadun; Kimberly P Cockerham
Journal:  Clin Pract       Date:  2021-12-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.